At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
BMS-986141 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS- 986141 For the Prevention of Recurrent Brain Infarction in Subjects Receiving Acetylsalicylic Acid (ASA) Following Acute Ischemic Stroke or Transient Ischemic Attack
In Brief
A Phase 2 clinical trial evaluating BMS-986141, Aspirin, and 1 other intervention for Thrombosis. Completed, enrolled 16 participants across 33 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are receiving acetylsalicylic acid (also known as aspirin or ASA) to treat the stroke or TIA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombosis
CountriesJapan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartApr 2016
Primary CompletionMar 2017
TodayJul 2026
First PostedFeb 2, 2016
Enrollment StartApr 25, 2016
Primary CompletionMar 31, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.4 years ago
Interventions
BMS-986141drug
Aspirindrug
Placeboother